English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose: HMG-CoA reductase inhibitors (statins) modulate the immune system and have anti-inflammatory effects. It has been proposed that their use in the peri-operative period may reduce surgical complications by modulating the post-operative pro-inflammatory response. This study aims to evaluate the effect of statins on surgical outcomes following colorectal cancer resection. Methods: A retrospective analysis of all colorectal cancer resections performed at University Hospital Birmingham, between June 2008 and July 2013, was conducted. Patients were divided into ‘Statin Users’ and ‘Non-statin Users’. Their outcomes and survival were evaluated using univariate, multivariate and cox-regression analysis. Results: 246/703 patients (35.0%) were statin users. There were no differences in disease stage between the groups. Statin users were found to have a higher proportion of colonic, compared to rectal, cancers than non-statin users (60.2% vs. 48.1%, p=0.0023) and a reduced incidence of stoma formation (OR 0.65, 95% CI 0.45-0.95, p=0.0280). Despite significant increases in age, BMI and co-morbidity, statin users had equivalent rates of complications, re-operations, re-admissions and mortality than non-statin users. Statin users were however more likely to be admitted to Critical Care (OR=1.83, 95% CI=1.16-2.87, p=0.0090) and have a prolonged hospital stay (12% increase in LOS, 95% CI=0.002-0.10, p=0.0420). No significant dose related differences were identified in patient outcomes and mortality were observed, although an overall risk reduction in mortality with increasing dose of statin remains possible (HR=0.67, 95% CI=0.41-1.09, p=0.1100). Conclusions: Statin users achieved equivalent short-term and long-term outcomes to non-statin users despite an increased operative risk and their use in the peri-operative period, particularly at high doses, merits further investigation.

Is HMG-Co A Reductase Inhibitor Use Associated with Improved Outcomes in Patients Undergoing Colorectal Cancer Resection?